2015 |
Ute Worringen |
The Humanitarian Device Exemption of the United States as a Pioneering Concept in Orphan Device Regulation and its Implications for the Policy of the Regulation of Medical Devices for Small Populations in the European Union *** |
|
|
2014 |
Noel Bettinville |
Current CMC Variation Regulation, change-control, and compliance - outline of a proposed CMC change implementation risk assessment & planning concept that embraces regulatory premises, supply chain forecasting, and quality systems |
|
|
2014 |
Christian Döring |
Regulatory burden, adequate to Allergen Specific Immunotherapy? *** |
|
|
2014 |
Dr. Alexandra Eckhoff |
Pharmacogenomic data in the product information of medicinal products *** |
|
|
2014 |
Claudia Engeler-Plischka |
Sunscreen products - drug or cosmetics? A Comparison of the legal requirements for sunscreen products in Europe, Australia and United States *** |
|
|
2014 |
Heike Fell |
Adaptive Design Clinical Trials *** |
|
|
2014 |
Dr. Monika Fürlinger |
A risk benefit analysis of Biosimilars |
|
|
2014 |
Julia Gröger |
Comparison of the Pediatric Drug Legislation between US and EU Food and Drug Administration Safety and Innovation Act (Title V) versus EU Paediatric Regulation (EC) No 1901/2006 *** |
|
|
2014 |
Katja Heiss |
EMA versus US-FDA regulatory requirements regarding bioequivalence of orally administered generics *** |
|
|
2014 |
Dr. Florian Herb |
Impact of polymorphism of active pharmaceutical ingredients on the development of generic medicinal products *** |
|
|
2014 |
Dr. Maria Iwe |
Commission Proposal for a Clinical Trials Regulation: implications for ethics committees |
|
|
2014 |
Dr. Katja Jennißen |
Adaptive Licensing – A new approach in medicinal product authorisation *** |
|
|
2014 |
Diana Jung |
Management of Worldwide Regional Regulatory CMC Requirements - An Approach by Creation of a CMC Database |
|
|
2014 |
Dr. Johanna Kuhlmann-Gottke |
Regulatory requirements regardings cell-based medicinal products for human and veterinary use in Germany and Europe - a comparison *** |
|
|
2014 |
Laura Liekmeier |
Best way to market for generics (DCP or CP) and the limitations due to a multi-brand marketing strategy |
|
|
2014 |
Dr. Klaus Löchner |
Inclusion of the German purely national marketing authorisations in the scope of the Variations Regulation and use of the new Classification Guideline of 2013 in practice compared to the previous guideline and the former national German variation system *** |
|
|
2014 |
Dr. Tina Lübbehüsen |
Real Time Release Testing - Challenges and Opportunities for the Pharmaceutical Industry |
|
|
2014 |
Natalie Lubrich |
Einfluss von DRA auf das Tendergeschäft in Deutschland – Strategien eines mittelständischen Generikaunternehmens |
|
|
2014 |
Dr. Sybille Meyer |
Animal Health market in the BRIC countries and comparison of its regulatory requirements for veterinary medicinal products with EU legislation *** |
|
|
2014 |
Dr. Margarita Muiños Gimeno |
Regulatory Submission: from paper submissions to RPS *** |
|
|